Edition:
United Kingdom

Molecular Templates Inc (MTEM.OQ)

MTEM.OQ on NASDAQ Stock Exchange Capital Market

7.08USD
13 Dec 2017
Change (% chg)

$-0.12 (-1.67%)
Prev Close
$7.20
Open
$7.14
Day's High
$7.16
Day's Low
$6.94
Volume
75,029
Avg. Vol
34,493
52-wk High
$11.88
52-wk Low
$3.90

Summary

Name Age Since Current Position

Harold Selick

62 2017 Chairman of the Board

Eric Poma

2017 Chief Executive Officer, Chief Scientific Officer, Director

Adam Cutler

43 2017 Chief Financial Officer

Conrad Jordaan

2017 Senior Vice President - Finance, Corporate Controller

Nenad Sarapa

2017 Senior Vice President - Clinical Development

Joel Fernandes

45 2011 Vice President - Finance, Controller

Mark Hopkins

2015 Vice President - Intellectual Property and Assistant General Counsel

Kristen Quigley

45 2016 Vice President - Clinical Operations

Barbara Ruskin

2017 General Counsel and Chief Patent Officer

Tillman Pearce

59 2012 Chief Medical Officer

Michael Broxson

2017 Director

David Hirsch

2017 Director

Kevin Lalande

44 2017 Director

Scott Morenstein

2017 Director

David Hoffmann

70 2007 Independent Director

Laura Hansen

IR Contact

Biographies

Name Description

Harold Selick

Dr. Harold E. Selick, Ph.D., is Chairman of the Board of Threshold Pharmaceuticals Inc., effective March 31, 2017. From June 2002 until July 2007, Dr. Selick was a Venture Partner of Sofinnova Ventures, Inc., a venture capital firm. From January 1999 to April 2002, he was Chief Executive Officer of Camitro Corporation, a biotechnology company. From 1992 to 1999, he was at Affymax Research Institute, the drug discovery technology development center for Glaxo Wellcome plc, most recently as Vice President of Research. Prior to working at Affymax he held scientific positions at Protein Design Labs, Inc. and Anergen, Inc. As a staff scientist at Protein Design Labs, Inc. (now PDL BioPharma, Inc., or PDL) he co-invented the technology underlying the creation of fully humanized antibody therapeutics and applied that to PDL’s first product, Zenapax (daclizumab), which was developed and commercialized by Roche for treating kidney transplant rejection. Dr. Selick serves on the board of directors of PDL, a public company and currently serves as Chairman of the Board of Directors of Catalyst Biosciences, a privately-held drug discovery and development company, serves as a director of InteKrin Therapeutics, a clinical-stage, privately-held biopharmaceutical company, and also serves as a director of Protagonist Therapeutics, a privately-held biotechnology company. Dr. Selick received his B.S. and Ph.D. from the University of Pennsylvania and was a Damon Runyon-Walter Winchell Cancer Fund Fellow and an American Cancer Society Senior Fellow at the University of California, San Francisco.

Eric Poma

Dr. Eric E. Poma is Chief Executive Officer, Chief Scientific Officer, Director of the company. Prior to the completion of the Merger, Dr. Poma was Chief Executive Officer and Chief Scientific Officer of Private Molecular, for which he served as a member of the board of directors since founding Private Molecular in February 2009. From March 2005 until September 2008, Dr. Poma was Vice President of Business Development of Innovive Pharmaceuticals (acquired by Cytrx Corporation), a biotechnology company. From 2001 to 2005, he served as the Associate Vice President of Business Development at ImClone Systems, Inc. (now Eli Lilly and Company), a biotechnology company focused on antibody therapeutics. As the founder and in his role as Chief Scientific Officer of Private Molecular, Dr. Poma led the invention of technology underlying Private Molecular’s platform technology and what constitutes the whole of Private Molecular’s current lead and preclinical pipeline candidates. Dr. Poma received his Ph.D. in Microbiology and Immunology and B.A. in Biology and from the University of North Carolina at Chapel Hill and his M.B.A. from New York University. The Registrant’s board of directors believes that Dr. Poma’s direct involvement in the creation of, and knowledge of, Private Molecular’s technology platform and extensive experience in the industry provides an invaluable insight to the Registrant’s board of directors on matters involving the Registrant and its future goals. The Registrant’s board of directors also believes that having Dr. Poma as a director is an optimal way of ensuring the most efficient execution and development of the Registrant’s business goals and strategies.

Adam Cutler

Mr. Adam D. Cutler is Chief Financial Officer of the Company. He joins the Company from Arbutus Biopharma, where he was Senior Vice President of Corporate Affairs, responsible for designing and executing Investor Relations programs. From 2012-2015, Mr. Cutler was a Managing Director for The Trout Group, where he advised public and private life science companies on investor relations and capital raising strategies. From 2011-2012, Mr. Cutler was Director and Senior Biotechnology Analyst for Credit Suisse, where he led the small and mid-cap biotechnology equity research team. Prior to that, he was Managing Director and Senior Biotechnology Analyst for Canaccord Genuity. Prior to Canaccord Genuity he held Biotechnology Analyst positions at JMP Securities LLC and at Bank of America Merrill Lynch (f/k/a Bank of America Securities). He also served as an Analyst in the Life Sciences Strategy & Market Assessments division of The Frankel Group and prior to that was a Consultant for Ernst & Young LLP for their Hospital, Healthcare, and Payor clients. Mr. Cutler currently serves on the Board of Directors for Inmed Pharmaceuticals, a preclinical stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based prescription drug therapies utilizing novel drug delivery systems, and serves as a Corporate Development Consultant for Roivant Sciences. He earned his Bachelor of Arts degree in Economics, with a minor in Law, Medicine, and Health Policy from Brandeis University.

Conrad Jordaan

Mr. Conrad Jordaan is Senior Vice President of Finance and Corporate Controller of the Company. He has more than 20 years of experience in accounting and finance. Before joining Molecular Templates and since 2014 he was the Corporate Controller at Cytokinetics. Prior to that, from 2011 to 2014 he was the Director, SEC Reporting and Technical Accounting at Onyx Pharmaceuticals. From 2010 to 2011, he was Associate Director, Financial Reporting and Treasury at Savient Pharmaceuticals. Prior to that, he spent 12 years with Ernst & Young in a variety of roles, most recently as Senior Manager in New Jersey from 2002 to 2009, and in Johannesburg, South Africa from 1995 to 2001; and as Senior Auditor with the National Audit Office in London, United Kingdom from 2001 to 2002. Mr. Jordaan earned an MBA in Finance and Global Business from the Leonard N. Stern School of Business, an Honours Bachelor of Accounting Science from the University of South Africa, and a Baccalaureus Commercii in Accounting from the University of Johannesburg

Nenad Sarapa

Dr. Nenad Sarapa is Senior Vice President - Clinical Development of the Company. He joined Molecular Templates in 2017 as SVP, Clinical Development. He has more than 22 years of experience in clinical research and development of novel oncology, anti-inflammatory and anti-infective agents, including small molecules, monoclonal antibodies, antibody-drug conjugates and antisense oligo therapeutics. Before joining Molecular Templates, beginning in 2013 he was Senior Director of Translational Medicine, Oncology, for Bayer Pharmaceuticals. From 2009 to 2012, Dr. Sarapa was Head of Clinical Pharmacology, Oncology for Hoffman-La Roche. Prior to that, he served as a group manager, project leader and clinical research physician in early clinical development for Johnson & Johnson from 2007 to 2009, Daiichi Sankyo, Inc. from 2005 to 2007, Pfizer, Inc. from 1999 to 2005, and GlaxoWellcome from 1995 to 1999. Dr. Sarapa earned his MD with a Fellowship in General Medicine and Clinical Pharmacology from the Medical School at the University of Zagreb, Croatia.

Joel Fernandes

Mr. Joel A. Fernandes is Vice President - Finance, Controller of Threshold Pharmaceuticals Inc. Prior to May 2011, Mr. Fernandes served as our Senior Director, Finance and Controller. Mr. Fernandes served as Associate Director of Finance at Theravance, Inc. from January 2005 to March 2006, Senior Manager of Corporate Finance at KLA-Tencor from August 2002 to January 2005 and Assistant Controller of ALZA Corporation from 1999 to 2002. Mr. Fernandes has been a Certified Public Accountant since 1996 and has a Masters in Accountancy from Manchester College, Indiana.

Mark Hopkins

Dr. Mark Hopkins J.D. Ph.D. is Vice President - Intellectual Property and Assistant General Counsel of the Company. In this newly created position, Dr. Hopkins oversees worldwide intellectual property strategy and activities related to further advancement of Threshold's intellectual property portfolio for its investigational anti-cancer therapeutics, evofosfamide and tarloxotinib, and hypoxia-activated prodrug technology. Dr. Hopkins is also responsible for oversight of corporate legal matters at Threshold.

Kristen Quigley

Ms. Kristen Quigley serves as Vice President - Clinical Operations of the Company. She served as the Company’s Executive Director of Clinical Operations from January 2016 until her promotion to Vice President of Clinical Operations on October 14, 2016. Prior to January 2016, Ms. Quigley served as the Company’s Senior Director of Clinical Operations since June 2014. Ms. Quigley served in positions of increasing responsibility, most recently as Project Management Senior Director of Icon PLC from August 2001 to June 2014. Ms. Quigley received her B.A. from Washington University in St. Louis.

Barbara Ruskin

Dr. Barbara A. Ruskin is General Counsel and Chief Patent Officer of the Company. She joined Molecular Templates in 2017 as SVP, General Counsel and Chief Patent Officer. Previously from 2015 to 2016, she served as SVP, General Counsel of Bionor Pharma and since May 2012 as President of BA Ruskin Law LLC where she advised biotechnology and pharmaceutical companies in worldwide patent portfolio management, litigation strategies, corporate transactions and due diligence. Barbara was a Partner at Ropes & Gray LLP in New York City from 2005 to 2012 and an Associate at Fish & Neave LLP from 1999 to 2005. She holds a J.D. from Fordham University School of Law, a Ph.D. in Biochemistry and Molecular Biology from Harvard University and a B.A. in Biochemistry from the University of California, Berkeley. She is admitted to practice law in New York State and is a registered U.S. patent attorney.

Tillman Pearce

Dr. Tillman Pearce, M.D., is Chief Medical Officer of Threshold Pharmaceuticals, Inc. Dr. Pearce served as Chief Medical Officer of KaloBios Pharmaceuticals, Inc., from 2007 through 2011, where he where he oversaw the design and execution of clinical programs for three antibody therapeutics in the fields of infectious disease, inflammation (asthma and rheumatoid arthritis and hematologic malignancies, and since 2011 and prior to joining us, he had been an oncology consultant. Prior to KaloBios, Dr. Pearce was a Senior Director at PDL BioPharma, Inc. from 2002 to 2007 and a Medical Director in the Oncology Business Unit at Sanofi-Synthelabo from 1997 to 2002. He has also held research positions in oncology at Sandoz and Novartis. Dr. Pearce holds a B.A. in philosophy from Tulane University and an M.D. from the Medical College of Georgia.

Michael Broxson

Mr. Michael Broxson is Director of the company since August 2017. He is currently Vice President and Head of R&D Business Development for Takeda Pharmaceuticals and is based in Cambridge, Massachusetts. Mr. Broxson has served in diverse leadership roles across finance, strategy, and business development at Takeda for 16 years. He has led or played significant roles in over 70 transactions, including the acquisitions of Millennium Pharmaceuticals, Inc., Nycomed and Envoy Therapeutics, and more recently established Takeda’s externalization practice to spin out Takeda assets through new ventures and innovative alliances. In overseeing the entirety of the portfolio of Takeda R&D transactions, Mr. Broxson brings a unique enterprise view of the Takeda organization and will provide the Registrant with a meaningful conduit for accessing resources and expertise as appropriate. Mr. Broxson holds degrees in Economics and Public Health from Tulane, has an M.B.A. from University of Chicago, Booth School of Business, and is a CFA Charter holder. The Registrant’s board of directors believes it benefits from Mr. Broxson’s industry knowledge and experience.

David Hirsch

Kevin Lalande

Mr. Kevin M. Lalande is Director of the company. He serves as a member of the Registrant’s board of directors and serves as a managing director of SHV Management Services, LLC, which is the general partner of SHV Management Services, LP which is the general partner of Santé Health Ventures I, L.P., and SHV Annex Services, LP, which is the general partner of Santé Health Ventures I Annex Fund, L.P.

Scott Morenstein

Mr. Scott Morenstein is Director of the company since August 2017. Mr. Morenstein serves as Managing Director of CAM Capital, where he leads healthcare private equity investing. CAM Capital was established in 2012 by Bruce Kovner following his retirement from Caxton Associates, the macro hedge fund he founded and managed from 1983 to 2011. Prior to joining CAM Capital in 2013, Mr. Morenstein served as Managing Director at Valence Life Sciences and before that Principal at Caxton Advantage Venture Partners, which he joined in 2007. Prior to joining Caxton Advantage, Mr. Morenstein served as an investment banking associate and founding member of Seaview Securities. Mr. Morenstein began his career at Lehman Brothers as a healthcare investment banker and equity research analyst. Mr. Morenstein has more than 15 years’ experience in biopharmaceutical investing, equity research and investment banking. Mr. Morenstein led CAM’s investment in and served as a Director of Celator Pharmaceuticals until its acquisition by Jazz Pharmaceuticals in July 2016. He was nominated a Director of Synta Pharmaceuticals to advise the company as it explored strategic alternatives ultimately leading to a merger with Madrigal Pharmaceuticals. He served as a member of Gemin X’s board until its acquisition by Cephalon. He currently serves as a Director of Velicept Therapeutics. Mr. Morenstein received an M.B.A. from Harvard Business School and a B.A. from the University of Pennsylvania with a degree in the Biological Basis of Behavior with a Concentration in the Physiology of Neural Systems. The Registrant’s board of directors believes it benefits from Mr. Morenstein’s industry and financial knowledge and experience.

David Hoffmann

Mr. David R. Hoffmann is Independent Director of Threshold Pharmaceuticals Inc. Mr. Hoffmann is retired from ALZA Corporation (now a Johnson & Johnson company) where he held the positions of Vice President and Treasurer from 1992 to until his retirement in October 2002, Vice President of Finance from 1982 to 1992 and Director of Accounting/Finance from 1976 to 1982. Mr. Hoffmann is currently Chief Executive Officer of Hoffmann Associates, a multi-group company specializing in cruise travel and financial and benefit consulting. He serves on the board of directors of DURECT Corporation. Mr. Hoffmann holds a B.S. in Business Administration from the University of Colorado.

Laura Hansen